Granulox^® is an oxygenating spray for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, arterial leg ulcers, and mixed leg ulcers for the secondary healing of surgical wounds and pressure sores   . It can also be used on healing of sloughy and infected wounds  .

When Granulox is sprayed on a wound, highly purified haemoglobin is released. This binds with oxygen from the environment and diffuses through the wound exudate, and the haemoglobin supplies the base of the wound topically with oxygen. The oxygen supply to the base of the wound supports wound healing and patient outcomes  .

A convenient spray application makes Granulox a portable and easy-to-use adjunct to standard of care wound treatment. Granulox can be applied when the wound dressing is changed, and at least every three days for optimal results.

Studies report that using Granulox results in shorter healing time, reduced pain scores and total cost savings for healthcare providers compared to standard of care .

• Twice as many chronic wounds healed at 8–16 weeks compared to standard of care  
• Time to heal diabetic foot ulcers 50% shorter than with standard of care  
• Treatment costs in diabetic foot ulcers at least 40% lower than with standard of care
• More than 70% of patients reported lower average pain scores at four weeks than with standard of care in chronic wounds  
• 99% less slough in chronic wounds after 4 weeks compared to 33% with standard of care  

My experience with Granulox

Alexandra Müller-Otte, wound care patient and passionate table tennis player, shares her thoughts on Granulox^® and the difference it made to her recovery after a major spinal surgery.

‘The wound is completely healed after six weeks. Even after two weeks, we thought ‘Wow! That is extreme!’… I was really thrilled.’ Alexandra Müller-Otte, Patient

NICE Medtech Innovation Briefing

The National Institute for Health and Care Excellence (NICE) has issued a new Medtech Innovation Briefing advising that Mölnlycke’s Granulox® Oxygen Therapy could lead to significant improvements in healing time and pain reduction for non-healing chronic wounds.

Patients treated with Granulox saw their wound size reduced by between 49% and 102% on average after 4 weeks. Studies also found average pain scores fell by between 49% and 78% in one group of patients.

When Granulox is sprayed on a wound after cleansing and debridement and before a dressing is applied, highly purified haemoglobin is released. This binds with oxygen from the environment and diffuses through the exudate to supply oxygen to the base of the wound, supporting wound healing and improving patient outcomes.

Granulox is intended for use alongside current treatment for people with non-healing chronic wounds that have not responded to standard care, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers.

FIND OUT MORE ABOUT THE NICE MIB HERE